Edinburgh Clinical Trials

Macrophage Therapy For Acute Liver Injury (MAIL)

The aim of this trial is to test the safety and tolerability of macrophage cell therapy in acute liver injury following paracetamol overdose.

Macrophage Therapy For Acute Liver Injury (MAIL) Trial: A Phase 1 Randomised, Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages (AAM) in Patients with Paracetamol-induced Acute Liver Injury.

MAIL macrophages in acute liver injury logo

Chief Investigator: Professor James Dear 

Number and location of participating sites (by region/ country): Single Centre, Edinburgh Royal Infirmary

ISRCTN number: TBC


Funder:  Medical Research Council

Start and End date

Of grant award: 01 December 2022 - 30 November 2025

Of recruitment: 01 Mat 2023 - 30 April 2025 (TBC)

Current Status: In set up

Email: MAIL.Trial@ed.ac.uk


Sponsor: University of Edinburgh and NHS Lothian -  https://www.accord.scot/


Chief Investigator:

Professor James Dear, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, james.dear@ed.ac.uk

Trial Manager:

Anna Heye, ECTU, University of Edinburgh, level 2, NINE Edinburgh BioQuarter 9 Little France Road  MAIL.Trial@ed.ac.uk


ECTU involvement: Trial Management, Statistics, Database